Physician profile
Jeditza Arroyo
NPI 1336480557
$382.97
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2021: $6.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $125.51 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.44 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.58 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $24.19 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.52 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.17 | 2019 | |
| Abbott Laboratories | $14.35 | 2019 | |
| Pfizer Pharmaceuticals LLC | $12.82 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.74 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeditza Arroyo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.